These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 21040440)

  • 1. Why is urine drug testing not used more often in practice?
    Bair MJ; Krebs EE
    Pain Pract; 2010; 10(6):493-6. PubMed ID: 21040440
    [No Abstract]   [Full Text] [Related]  

  • 2. The role of urine drug testing for patients on opioid therapy.
    Pergolizzi J; Pappagallo M; Stauffer J; Gharibo C; Fortner N; De Jesus MN; Brennan MJ; Richmond C; Hussey D;
    Pain Pract; 2010; 10(6):497-507. PubMed ID: 20412503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A systematic approach to identifying drug-seeking patients.
    Pretorius RW; Zurick GM
    Fam Pract Manag; 2008 Apr; 15(4):A3-5. PubMed ID: 18444310
    [No Abstract]   [Full Text] [Related]  

  • 4. [Urine testing in the treatment of opiate addiction].
    Ege PP
    Ugeskr Laeger; 2003 Mar; 165(13):1346-8. PubMed ID: 12703279
    [No Abstract]   [Full Text] [Related]  

  • 5. Importance of urine drug testing in the treatment of chronic noncancer pain: implications of recent medicare policy changes in kentucky.
    Gilbert JW; Wheeler GR; Mick GE; Storey BB; Herder SL; Richardson GB; Watts E; Gyarteng-Dakwa K; Marino BS; Kenney CM; Siddiqi M; Broughton PG
    Pain Physician; 2010; 13(2):167-86. PubMed ID: 20309383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. False-positive urine opiate screening associated with fluoroquinolone use.
    Zacher JL; Givone DM
    Ann Pharmacother; 2004 Sep; 38(9):1525-8. PubMed ID: 15252190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of a polyethylene glycol marker system in urine drug screening in an opiate substitution program.
    Schneider HJ; Rühl B; Meyer K; Keller R; Backmund M
    Eur Addict Res; 2008; 14(4):186-9. PubMed ID: 18583915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of reported drug use and urinalysis in the assessment of drug use.
    Jain R; Tripathi BM; Singh R
    Natl Med J India; 2001; 14(5):315-6. PubMed ID: 11767230
    [No Abstract]   [Full Text] [Related]  

  • 9. The use of novel hair testing techniques to detect highly labile components documenting heroin abuse and single dosage use of other opiates.
    Soper J
    Aviat Space Environ Med; 2008 Apr; 79(4):451. PubMed ID: 18457307
    [No Abstract]   [Full Text] [Related]  

  • 10. Detection of benzodiazepine abuse in opiate addicts.
    Browne R; Sloan D; Fahy S; Keating S; Moran C; O'Connor J
    Ir Med J; 1998; 91(1):18-9. PubMed ID: 9563249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The GC-MS detection and characterization of reticuline as a marker of opium use.
    Al-Amri AM; Smith RM; El-Haj BM; Juma'a MH
    Forensic Sci Int; 2004 Mar; 140(2-3):175-83. PubMed ID: 15036439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Urine drug screening: necessary or alienating?
    Darnall BD; Schatman ME
    Pain Med; 2014 Dec; 15(12):1999. PubMed ID: 25376375
    [No Abstract]   [Full Text] [Related]  

  • 13. Re: The role of urine drug testing for patients on opioid therapy.
    Collen MR
    Pain Pract; 2011; 11(2):199; author reply 199. PubMed ID: 21371255
    [No Abstract]   [Full Text] [Related]  

  • 14. Down the drain: Reconsidering routine urine drug testing during the COVID-19 pandemic.
    Pytell JD; Rastegar DA
    J Subst Abuse Treat; 2021 Jan; 120():108155. PubMed ID: 33298297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urine drug screening: opioid risks preclude complete patient autonomy.
    Darnall BD; Schatman ME
    Pain Med; 2014 Dec; 15(12):2001-2. PubMed ID: 25376661
    [No Abstract]   [Full Text] [Related]  

  • 16. Comparison of three commercial tests for buprenorphine screening in urine.
    Leino A; Loo BM
    Ann Clin Biochem; 2007 Nov; 44(Pt 6):563-5. PubMed ID: 17961313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Program monitoring for clinical practice. Specimen positivity across urine collection methods.
    Moran J; Mayberry C; Kinniburgh D; James D
    J Subst Abuse Treat; 1995; 12(3):223-6. PubMed ID: 7474030
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Few benefits, likely harms: against universal random urine drug screening in pain management.
    Goldberg DS; Rich BA
    Pain Med; 2014 Dec; 15(12):2000-1. PubMed ID: 25376562
    [No Abstract]   [Full Text] [Related]  

  • 19. Pupillometry in the detection of concomitant drug use in opioid-maintained patients.
    Murillo R; Crucilla C; Schmittner J; Hotchkiss E; Pickworth WB
    Methods Find Exp Clin Pharmacol; 2004 May; 26(4):271-5. PubMed ID: 15319805
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Opiates].
    Nomoto T
    Nihon Rinsho; 2004 Dec; 62 Suppl 12():469-71. PubMed ID: 15658365
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.